Biomarkers Based EArly Diagnosis of STroke Subtype Cohort(Bio-EAST)
Launched by SHANGHAI EAST HOSPITAL · May 26, 2025
Trial Information
Current as of August 19, 2025
Not yet recruiting
Keywords
ClinConnect Summary
The Bio-EAST trial is studying a new way to quickly diagnose a type of stroke called intracerebral hemorrhage (ICH), which can lead to serious health issues or even death. Researchers want to see if a special protein called GFAP, which is found in the blood, can help doctors diagnose ICH faster and more accurately. By doing this, they hope to improve treatment outcomes for patients by starting important blood pressure treatment right away, even before they reach the hospital. This trial will also look at other markers in the blood that might help improve the accuracy of the diagnosis.
To participate in this trial, you need to be at least 18 years old and have symptoms of a stroke when you arrive at the emergency department. This includes signs like limb weakness. However, people who are in a coma, have serious health conditions, or have had recent head injuries won't be eligible. If you join the trial, you can expect to undergo tests that measure the levels of GFAP and possibly other biomarkers to help determine the best course of action for your treatment. It’s important to know that this trial is still in the planning stages and has not started recruiting participants yet.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Age ≥ 18 years old;
- • 2. Suspected stroke at emergency department arrival (FAST score ≥ 2 points, must include limb weakness);
- • 3. Time of stroke symptom onset/last known normal within 3 hours.
- Exclusion Criteria:
- • 1. Coma - no response to tactile or verbal stimuli;
- • 2. Severe comorbidities (such as tumors, severe COPD, severe heart failure, requiring assistance with daily living \[unable to walk independently\]);
- • 3. History of epilepsy or onset with seizure;
- • 4. Recent history of head trauma (\< 7 days);
- • 5. Blood glucose \< 2.8 mmol/L.
About Shanghai East Hospital
Shanghai East Hospital, affiliated with Tongji University, is a leading healthcare institution in China dedicated to providing high-quality medical services, education, and research. Renowned for its advanced clinical practices and cutting-edge technologies, the hospital plays a pivotal role in the advancement of medical science through innovative research and clinical trials. Committed to improving patient outcomes, Shanghai East Hospital collaborates with various stakeholders to explore new therapies and treatment modalities, enhancing the collective understanding of health and disease. Their clinical trial initiatives focus on addressing pressing medical needs while ensuring the highest ethical standards and patient safety.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Shanghai, Shanghai, China
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported